{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:06:14Z","timestamp":1794661574588,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Roche France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1190-z","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T11:05:15Z","timestamp":1481627115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis"],"prefix":"10.1186","volume":"18","author":[{"given":"J\u00e9r\u00e9mie","family":"Sellam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Courties","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Olivier","family":"Rouzaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Tolusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bineta","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houria","family":"Hendel Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Taoufik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"issue":"2","key":"1190_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","volume":"10","author":"FY Liew","year":"2010","unstructured":"Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10(2):103\u201310.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1190_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.114.222505","volume":"354","author":"TC Theoharides","year":"2015","unstructured":"Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther. 2015;354(1):24\u201331.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1190_CR3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/rheumatology\/kes409","volume":"52","author":"NL Millar","year":"2013","unstructured":"Millar NL, Murrell GAC, McInnes IB. Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatol Oxf Engl. 2013;52(5):769\u201379.","journal-title":"Rheumatol Oxf Engl"},{"issue":"5","key":"1190_CR4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479\u201390.","journal-title":"Immunity"},{"issue":"6","key":"1190_CR5","first-page":"3472","volume":"185","author":"B Stolarski","year":"2010","unstructured":"Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol Baltim Md 1950. 2010;185(6):3472\u201380.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"31","key":"1190_CR6","doi-asserted-by":"crossref","first-page":"10913","DOI":"10.1073\/pnas.0801898105","volume":"105","author":"D Xu","year":"2008","unstructured":"Xu D, Jiang H-R, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A. 2008;105(31):10913\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1190_CR7","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.4049\/jimmunol.0902685","volume":"184","author":"D Xu","year":"2010","unstructured":"Xu D, Jiang H-R, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol. 2010;184(5):2620\u20136.","journal-title":"J Immunol"},{"issue":"1","key":"1190_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-016-1042-x","volume":"18","author":"SK Athari","year":"2016","unstructured":"Athari SK, Poirier E, Biton J, Semerano L, Herv\u00e9 R, Raffaillac A, et al. Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Arthritis Res Ther. 2016;18(1):143.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1190_CR9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3892\/ijmm.2012.883","volume":"29","author":"E Kunisch","year":"2012","unstructured":"Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-\u03b1 dependent effects in synovial fibroblasts. Int J Mol Med. 2012;29(4):530\u201340.","journal-title":"Int J Mol Med"},{"issue":"7","key":"1190_CR10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/0022034515577815","volume":"94","author":"J Malcolm","year":"2015","unstructured":"Malcolm J, Awang RA, Oliver-Bell J, Butcher JP, Campbell L, Adrados Planell A, et al. IL-33 exacerbates periodontal disease through induction of RANKL. J Dent Res. 2015;94(7):968\u201375.","journal-title":"J Dent Res"},{"key":"1190_CR11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cyto.2015.10.005","volume":"77","author":"E-J Lee","year":"2016","unstructured":"Lee E-J, So MW, Hong S, Kim Y-G, Yoo B, Lee C-K. Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis. Cytokine. 2016;77:35\u201343.","journal-title":"Cytokine."},{"issue":"1","key":"1190_CR12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cyto.2011.12.010","volume":"58","author":"Z Xiangyang","year":"2012","unstructured":"Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine. 2012;58(1):6\u20139.","journal-title":"Cytokine"},{"issue":"1","key":"1190_CR13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2015.02.001","volume":"45","author":"J Shen","year":"2015","unstructured":"Shen J, Shang Q, Wong C-K, Li EK, Wang S, Li R-J, et al. IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: a prospective study. Semin Arthritis Rheum. 2015;45(1):18\u201327.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1190_CR14","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar4143","volume":"15","author":"P Martin","year":"2013","unstructured":"Martin P, Talabot-Ayer D, Seemayer CA, Vigne S, Lamacchia C, Rodriguez E, et al. Disease severity in K\/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther. 2013;15(1):R13.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1190_CR15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2014.05.007","volume":"69","author":"D Talabot-Ayer","year":"2014","unstructured":"Talabot-Ayer D, Martin P, Seemayer CA, Vigne S, Lamacchia C, Finckh A, et al. Immune-mediated experimental arthritis in IL-33 deficient mice. Cytokine. 2014;69(1):68\u201374.","journal-title":"Cytokine"},{"issue":"9","key":"1190_CR16","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/art.39192","volume":"67","author":"F Rivellese","year":"2015","unstructured":"Rivellese F, Suurmond J, Habets K, Dorj\u00e9e AL, Ramamoorthi N, Townsend MJ, et al. Ability of interleukin-33- and immune complex-triggered activation of human mast cells to down-regulate monocyte-mediated immune responses. Arthritis Rheumatol Hoboken NJ. 2015;67(9):2343\u201353.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"4","key":"1190_CR17","first-page":"2584","volume":"186","author":"M Komai-Koma","year":"2011","unstructured":"Komai-Koma M, Gilchrist DS, McKenzie ANJ, Goodyear CS, Xu D, Liew FY. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol Baltim Md 1950. 2011;186(4):2584\u201391.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"2","key":"1190_CR18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/sji.12312","volume":"82","author":"A Ahmed","year":"2015","unstructured":"Ahmed A, Koma MK. Interleukin-33 triggers B1 cell expansion and its release of monocyte\/macrophage chemoattractants and growth factors. Scand J Immunol. 2015;82(2):118\u201324.","journal-title":"Scand J Immunol"},{"key":"1190_CR19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaut.2014.01.032","volume":"50","author":"S Sattler","year":"2014","unstructured":"Sattler S, Ling G-S, Xu D, Hussaarts L, Romaine A, Zhao H, et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun. 2014;50:107\u201322.","journal-title":"J Autoimmun."},{"issue":"8","key":"1190_CR20","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.38671","volume":"66","author":"J Sellam","year":"2014","unstructured":"Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon H-J, Rouanet S, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol Hoboken NJ. 2014;66(8):2015\u201325.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"8","key":"1190_CR21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","volume":"73","author":"X Mariette","year":"2014","unstructured":"Mariette X, Rouanet S, Sibilia J, Combe B, Le Lo\u00ebt X, Tebib J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1190_CR22","first-page":"705","volume":"26","author":"AM Gestel van","year":"1999","unstructured":"van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol. 1999;26(3):705\u201311.","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"1190_CR23","first-page":"S1279","volume":"66","author":"J Sellam","year":"2014","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, Vernet N, Ly B, Marion-Thore S, et al. Serum IL-33 level is increased in rheumatoid arthritis and predicts response to rituximab in combination with high serum IgG level and autoantibody positivity: an open-label, prospective, multicentre biological trial. Arthritis Rheum. 2014;66 Suppl 10:S1279\u201380.","journal-title":"Arthritis Rheum."},{"issue":"3","key":"1190_CR24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/annrheumdis-2015-208557","volume":"75","author":"E Rivi\u00e8re","year":"2016","unstructured":"Rivi\u00e8re E, Ly B, Boudaoud S, Chavez H, Nocturne G, Chanson P, et al. Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sj\u00f6gren syndrome: comparison of different kits. Ann Rheum Dis. 2016;75(3):633\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1190_CR25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Lo\u00ebt X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(4):933\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1190_CR26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/acr.21865","volume":"65","author":"M Couderc","year":"2013","unstructured":"Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res. 2013;65(4):648\u201352.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1190_CR27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.coph.2013.03.006","volume":"13","author":"M Broek van den","year":"2013","unstructured":"van den Broek M, Visser K, Allaart CF, Huizinga TWJ. Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol. 2013;13(3):463\u20139.","journal-title":"Curr Opin Pharmacol"}],"updated-by":[{"DOI":"10.1186\/s13075-017-1221-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T00:00:00Z","timestamp":1485129600000}}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1190-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T13:18:11Z","timestamp":1568639891000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1190-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1190-z","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13075-017-1221-4","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"294"}}